Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Harpreet Singh, Liam Wilson, Tom Tencer & Jinender Kumar. (2023) Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis. ClinicoEconomics and Outcomes Research 15, pages 125-138.
Read now
Read now
Alok Chandra, Ravi Kanth & Sandeep Thareja. (2019) Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up. Biologics: Targets and Therapy 13, pages 191-200.
Read now
Read now
Nathalie C. Gemayel, Eugenio Rizzello, Petar Atanasov, Daniel Wirth & Andras Borsi. (2019) Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence. Current Medical Research and Opinion 35:11, pages 1911-1923.
Read now
Read now
Erika Lehtola, Johanna Haapamäki & Martti A. Färkkilä. (2016) Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up. Scandinavian Journal of Gastroenterology 51:12, pages 1476-1481.
Read now
Read now
William J. Sandborn, Atsushi Sakuraba, Anthony Wang, Dendy Macaulay, William Reichmann, Song Wang, Jingdong Chao & Martha Skup. (2016) Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. Current Medical Research and Opinion 32:7, pages 1233-1241.
Read now
Read now
Articles from other publishers (11)
Edo H J Savelkoul, Pepijn W A Thomas, Lauranne A A P Derikx, Nathan den Broeder, Tessa E H Römkens & Frank Hoentjen. (2022) Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis. Inflammatory Bowel Diseases.
Crossref
Crossref
Shiro Nakamura, Teita Asano, Hiroaki Tsuchiya, Kanami Sugimoto, Yuya Imai, Seiji Yokoyama & Yasuo Suzuki. (2022) Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance. Intestinal Research 20:3, pages 329-341.
Crossref
Crossref
Yong Il Lee, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim & Jae Hee Cheon. (2021) Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis. Gut and Liver 15:2, pages 232-242.
Crossref
Crossref
Vito Annese, Rahul Nathwani, Maryam Alkhatry, Ahmad Al-Rifai, Sameer Al Awadhi, Filippos Georgopoulos, Ahmad N. Jazzar, Ahmed M. Khassouan, Zaher Koutoubi, Mazen S. Taha & Jimmy K. Limdi. (2021) Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates. Therapeutic Advances in Gastroenterology 14, pages 175628482110653.
Crossref
Crossref
Kindra Dawn Clark-Snustad, Anand Singla & Scott David Lee. (2019) Efficacy of Infliximab in Crohn’s Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists. Digestive Diseases and Sciences 64:7, pages 1952-1958.
Crossref
Crossref
Fabio Salvatore Macaluso, Flaminia Cavallaro, Carla Felice, Marta Mazza, Alessandro Armuzzi, Paolo Gionchetti, Maurizio Vecchi & Ambrogio Orlando. (2019) Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. Digestive and Liver Disease 51:5, pages 613-620.
Crossref
Crossref
Anne S. Strik, Yow-Ming C. Wang, Laura E. Ruff, William Yashar, Bradley T. Messmer & Diane R. Mould. (2018) Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?. The AAPS Journal 20:6.
Crossref
Crossref
Marina Aloi, Matteo Bramuzzo, Serena Arrigo, Claudio Romano, Giulia D’Arcangelo, Doriana Lacorte, Simona Gatti, Maria T. Illiceto, Francesca Zucconi, Dario Dilillo, Giovanna Zuin, Daniela Knafelz, Alberto Ravelli, Salvatore Cucchiara & Patrizia Alvisi. (2018) Efficacy and Safety of Adalimumab in Pediatric Ulcerative Colitis: A Real-life Experience from the SIGENP-IBD Registry. Journal of Pediatric Gastroenterology & Nutrition 66:6, pages 920-925.
Crossref
Crossref
Patrícia ZACHARIAS, Aderson Omar Mourão Cintra DAMIÃO, Antonio Carlos MORAES, Fábio Vieira TEIXEIRA, Juliano Coelho LUDVIG, Rodrigo Bremer NONES, Rogerio SAAD-HOSSNE, Ligia Yukie SASSAKI, Rosemary Pereira Lino da SILVA, Luiza FACCHIN, Marcia OLANDOSKI & Paulo Gustavo KOTZE. (2017) ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY. Arquivos de Gastroenterologia 54:4, pages 321-327.
Crossref
Crossref
Sine Buhl, Casper Steenholdt, Maria Rasmussen, Märta K. Borghede, Jørn Brynskov, Ole Ø. Thomsen & Mark A. Ainsworth. (2017) Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 23:7, pages 1210-1217.
Crossref
Crossref
Marisa Iborra, Javier Pérez-Gisbert, Marta Maia Bosca-Watts, Alicia López-García, Valle García-Sánchez, Antonio López-Sanromán, Esther Hinojosa, Lucía Márquez, Santiago García-López, María Chaparro, Montserrat Aceituno, Margalida Calafat, Jordi Guardiola, Blanca Belloc, Yolanda Ber, Luis Bujanda, Belén Beltrán, Cristina Rodríguez-Gutiérrez, Jesús Barrio, José Luis Cabriada, Montserrat Rivero, Raquel Camargo, Manuel van Domselaar, Albert Villoria, Hugo Salata Schuterman, David Hervás & Pilar Nos. (2016) Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients. Journal of Gastroenterology 52:7, pages 788-799.
Crossref
Crossref